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Abstract: Melanin-Concentrating Hormone (MCH) is one of the most relevant 
orexigenic factors specifically located in the lateral hypothalamic area 
(LHA), with its physiological relevance demonstrated in studies using 
several genetically manipulated mice models. However, the central 
mechanisms controlling MCH-induced hyperphagia remain largely 
uncharacterized. Here, we show that central injection of MCH in mice 
deficient for kappa opoid receptor (k-OR) failed to stimulate feeding. To 
determine the hypothalamic area responsible for this MCH/k-OR 
interaction, we performed virogenetic studies and found that 
downregulation of k-OR by adeno-associated viruses (shOprk1-AAV) in LHA, 
but not in other hypothalamic nuclei, was sufficient to block MCH-induced 
food intake. Next, we sought to investigate the molecular signaling 
pathway within the LHA that mediates acute central MCH stimulation of 
food intake. We found that MCH activates k-OR and that increased levels 
of phosphorylated extracellular signal regulated kinase (ERK) are 
associated with downregulation of phospho-S6 Ribosomal Protein. This 
effect was prevented when a pharmacological inhibitor of k-OR was co-
administered with MCH. Finally, the specific activation of the direct 
upstream regulator of S6 (p70S6K) in the LHA attenuated MCH-stimulated 
food consumption. Our results reveal that lateral hypothalamic k-OR 
system modulates the orexigenic action of MCH via the p70S6K/S6 pathway. 
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Dear Editor, 
 
We will be grateful if the enclosed Ms entitled “Melanin-Concentrating Hormone 
acts through hypothalamic kappa opioid system and p70S6K to stimulate acute 
food intake” could be considered for publication as an Original Article at 
Neuropharmacology. 
 
We confirm that this work is original and has not been published elsewhere nor is it 
currently under consideration for publication elsewhere. 
 
All authors listed have contributed sufficiently to the project to be included as authors. 
To the best of our knowledge, no conflict of interest exists. We have included funding 
sources after the discussion. 
 
MCH is an orexigenic neuropeptide specifically located in the lateral hypothalamus that 
increases food intake and adiposity, having a strong impact in energy homeostasis. In 
the present study, by a combination of genetic and pharmacological approaches we 
uncover that its acute orexigenic effect is mediated via the k-OR system. In addition, we 
carry out some detailed mechanistic studies showing that the p70S6K/S6 signaling 
pathway in the lateral hypothalamic area (LHA) mediates MCH-induced feeding. More 
specifically, the highlights of our manuscript are: 
 
- Central MCH fails to stimulate food intake in k-OR-deficient mice. 
- Only k-OR specifically located in the LHA modulates MCH-induced feeding. 
- Central MCH activates k-OR in the LHA, and reduces phosphorylated levels of 
S6 ribosomal protein. This effect is blunted in rats pre-treated with a specific k-
OR antagonist. 
- The genetic activation of p70S6K in the LHA reduces MCH-induced feeding. 
 
Cover letter
These findings are quite significant because despite the fact that the orexigenic effect of 
MCH has been reported almost two decades ago; the involved hypothalamic molecular 
pathways remain largely unknown. 
 
Sincerely yours,  
 
 
 
 
 
 
Ruben Nogueiras, PhD 
Reviewer 1: 
As acknowledged by the authors, the reduced hyperphagic effect of MCH led to by the 
knockdown of k-OR in the LH was less than that produced for the i.c.v. injection of k-
OR antagonists. They attributed the reduced effect to the possibility that a "lower 
number of neurons are affected by the virogenetic approach". This could be a valid 
explanation. However, the authors cannot exclude the possibility that the MCH action 
through the k-OR occur in regions other than the LH. Indeed, the nucleus Accumbens 
(NAc) appears as good target as the LH for the k-OR-mediated effects of MCH. MCH-
R1 is strongly expressed in the NAc and k-OR agonists are known to act in the NAc. 
 
REPLY:		
We	completely	agree	with	 the	 reviewer.	We	cannot	 rule	out	 the	possibility	of	extra-
hypothalamic	 MCH	 actions	 through	 the	 kappa	 opioid	 receptor	 system.	 Indeed,	 the	
possibility	 of	 this	 interaction	 in	 the	 NAc	 is	 quite	 feasible	 since	 the	MCHR1	 is	 highly	
expressed	 in	 this	 area.	 In	 fact,	 we	 plan	 to	 address	 this	 issue	 and	 its	 functional	
significance	in	the	future	but	feel	that	is	out	of	the	scope	of	the	current	manuscript.	In	
the	current	study,	we	have	focused	on	hypothalamic	MCH/k-OR	interaction	to	simplify	
the	complex	central	mechanisms	 involved	on	 food	 intake	regulation	considering	 that	
MCHR	 and	 kappa	 opioid	 receptor	 are	 widely	 expressed	 within	 the	 central	 nervous	
system.		
We	do	consider	 the	comment	 from	the	 reviewer	very	appropriate,	and	will	highlight	
this	issue	by	adding	the	following	sentence:		
	“Moreover,	we	cannot	rule	out	a	potential	extra-hypothalamic	MCH	action	through	k-
OR	system.	Indeed,	a	good	candidate	is	the	NAc	where	MCHR1	is	strongly	expressed.	
Further	studies	to	address	this	issue	are	clearly	merited”.	
 
Reviewer 2: 
I have a concern regarding the colocalization MCHR/KOR. This was done with 
antibodies which specificity needs to be proven. To have worked with commercial 
antibodies directed at GPCRs I can attest that the majority are not selective. I know of 
researchers who wanted to raise antisera to the MCHR and never found specificity. The 
authors need to test these antibodies and not only accept the data of the companies 
which established them. 
 
REPLY:	
We	share	the	reviewer’s	concerns	regarding	antibody	specificity	and	it	is	something	we	
critically	appraise	in	our	papers.	For	the	ones	used	in	this	manuscript	we	have	carried	
out	 different	 validation	 procedures	 to	 test	 their	 reliability.	 Some	 of	 the	 information	
related	to	this	issue	was	already	reported	in	previous	papers	(e.g.	see	Imbernon	et	al.,	
Gastroenterology,	2013,	and	Imbernon	et	al.,	Hepatology,	2016),	and	we	did	not	find	it	
appropriate	 to	 redo	 the	 experiments	 here.	 Nevertheless,	 please	 allow	 us	 to	
recapitulate	some	of	this	information	about	the	rabbit-MCHR	(Abnova	PAB16225)	and	
goat	anti-k-OR	(Sigma	SAB2501442)	antibodies.	
Regarding	 MCHR	 we	 first	 performed	 standard	 validation	 methods	 (with/without	
primary	antibodies)	that	exhibited	specific	hypothalamic	staining	as	shown	below:	
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This	specificity	was	further	validated	using	a	combination	of	genetic	knock-down	of	the	
receptor	and	WB.	When	we	knock-down	MCHR	by	shRNA-viral	particles	specifically	in	
the	 lateral	 Hypothalamic	 area	 (LHA),	 the	 protein	 expression	 of	 MCHR	 analyzed	 by	
western	 blot	 is	 significantly	 reduced	 as	 shown	 in	 the	 figure	 below	 (Figure	 2A	 from	
Imbernon	et	al.,	Hepatology,	2016):	
	
Similarly,	 in	 the	 present	 study,	 the	 genetic	 down-regulation	 of	 k-OR	 in	 specific	
hypothalamic	 areas	 (paraventricular	 nucleus,	 PVH	 and	 LHA)	 using	 a	 shOprk1-AAV	
clearly	resulted	to	a	significant	decrease	in	k-OR	protein	expression	tested	by	different	
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techniques	 such	 as	 immunohistochemistry	 (for	 PVH)	 and	 western	 blot	 (for	 LHA)	
(Figures	2E-F,	H):	
	
	
	
	
	
	
	In	 addition,	 using	 the	 goat	 anti-k-OR	 (Sigma	 SAB2501442)	 antibody	 it	 has	 been	
demonstrated	 a	 positive	 and	 negative	 k-OR	 immunoreactivity	 for	 tdTomato	 cells	
expressing	MCHR1	(Figure	3E,	Imbernon	et	al.,	Hepatology,	2016):		
	
	
	
	
Some	of	 these	assays	were	carried	out	 in	 the	 laboratory	of	Dr.	 Zsolt	 Liposits,	who	 is	
one	of	the	most	reputed	scientists	in	the	field	of	brain	immunohistochemistry.		
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Another concern is that KOR is significantly expressed on MCH expressing neurons. 
The authors need to analyze their data with this caveat in mind. 
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unclear.	We	feel	that	our	data	showing	that	exogenous	pharmacological	blockade	with	
k-OR-antagonists	block	exogenous	MCH-induced	food	intake	indicates	that	the	k-OR	is	
exerting	its	effect	downstream	of	the	MCHR.	Having	said	that,	we	share	the	reviewer’s	
view	 that	 the	 functional	 interaction	 of	 the	 k-OR-	 and	 MCH-systems	 is	 likely	 to	 go	
further	than	the	effect	here	described.	The	presence	of	k-OR	in	MCH	neurons	indicates	
that	the	activity	of	MCH	neurons	 is	also	regulated	by	endogenous	opioid-neurons.	 In	
fact,	it	is	known	that	dynorphin	neurons	are	co-localized	with	MCHR1	neurons	(Chee	et	
al	2013).	Therefore,	these	findings	provide	the	anatomical	and	biochemical	substrate	
of	a	 strong	 functional	 relationships	among	both	 systems.	Whether	 this	 interaction	 is	
related	to	energy	balance	remains	to	be	established.		
	
We	have	now	added	the	following	text	to	the	discussion:	“Nevertheless,	it	is	becoming	
clear	 that	 the	 functional	 interaction	 of	 the	 k-OR-	 and	 MCH-systems	 is	 likely	 to	 go	
further	than	the	effect	described	here.	The	presence	of	k-OR	in	MCH	neurons	indicates	
that	the	activity	of	MCH	neurons	 is	also	regulated	by	endogenous	opioid-neurons.	 In	
fact	it	is	known	that	dynorphin	neurons	are	co-localized		with	MCHR1		neurons	(Chee	
et	al	2013)		and	that		k-OR	is	co-localized	with	MCH	neurons	(Parks	et	al.,	2014).	These	
anatomical	and	biochemical	findings	imply	strong	functional	relationships	between	the	
two	systems.	Further	studies	assessing	the	role	of	the	k-OR	as	a	potential	mediator	of	
MCH	in	other	brain	systems	like	dopaminergic	reward	areas	such	as	the	NAc	and	VTA	
are	warranted.	Similarly,	 the	 functional	significance	of	 the	k-OR	 in	MCH	neurons	and	
putative	regulation	by	endogenous	opioid	peptides	needs	to	be	uncovered”.	
	
Finally,	a	new	reference	(Parks	et	al.,	2014)	has	been	added	to	the	references	list	in	the	
manuscript	(highlight).		
 
 
 
The highlights of our manuscript are: 
 
- Central MCH fails to stimulate food intake in k-OR-deficient mice. 
-  k-OR, in the lateral hypothalamic area (LHA), modulates acute MCH-induced 
feeding. 
- Central MCH activates k-OR in the LHA, and reduces phosphorylated levels of 
S6 ribosomal protein.  
- The genetic activation of p70S6K in the LHA reduces MCH-induced feeding. 
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ABSTRACT 
 Melanin-Concentrating Hormone (MCH) is one of the most relevant orexigenic 
factors specifically located in the lateral hypothalamic area (LHA), with its 
physiological relevance demonstrated in studies using several genetically manipulated 
mice models. However, the central mechanisms controlling MCH-induced hyperphagia 
remain largely uncharacterized. Here, we show that central injection of MCH in mice 
deficient for kappa opoid receptor (k-OR) failed to stimulate feeding. To determine the 
hypothalamic area responsible for this MCH/k-OR interaction, we performed 
virogenetic studies and found that downregulation of k-OR by adeno-associated viruses 
(shOprk1-AAV) in LHA, but not in other hypothalamic nuclei, was sufficient to block 
MCH-induced food intake. Next, we sought to investigate the molecular signaling 
pathway within the LHA that mediates acute central MCH stimulation of food intake. 
We found that MCH activates k-OR and that increased levels of phosphorylated 
extracellular signal regulated kinase (ERK) are associated with downregulation of 
phospho-S6 Ribosomal Protein. This effect was prevented when a pharmacological 
inhibitor of k-OR was co-administered with MCH. Finally, the specific activation of the 
direct upstream regulator of S6 (p70S6K) in the LHA attenuated MCH-stimulated food 
consumption. Our results reveal that lateral hypothalamic k-OR system modulates the 
orexigenic action of MCH via the p70S6K/S6 pathway. 
 
Keywords:  
Hypothalamus, Melanin-Concentrating Hormone, kappa-opioid receptor, food intake. 
 
Chemical compounds studied in this article: 
Melanin-Concentrating Hormone (MCH) (PubChem CID: 24868207) 
Naloxone Hydrochloride (PubChem CID: 5464092) 
Norbinaltorphimine dyhydrochloride (norBNI) (PubChem CID: 5480230) 
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1. Introduction 
 
 In mammals, MCH is a cyclic 19-amino acid neuropeptide synthesized in the 
LHA and zona incerta (ZI). This neuropeptide is a critical hypothalamic regulator of 
energy homeostasis, having effects on both feeding behavior and energy expenditure. 
Central administration (Qu et al., 1996), or transgenic overexpression (Ludwig et al., 
2001) of MCH increases food intake, whereas deletion of MCH (Alon and Friedman, 
2006; Shimada et al., 1998) or its receptor (Chen et al., 2002) reduces body weight. In 
addition, MCH can modulate glucose metabolism (Kong et al., 2010; Ludwig et al., 
2001) and peripheral lipid metabolism in the white adipose tissue (Imbernon et al., 
2013) and liver (Imbernon et al., 2016; Pissios et al., 2006). Although it is well 
recognized that MCH acts in a way to preserve energy, the molecular mechanisms 
underlying MCH action are poorly understood. Previous studies indicate that MCH 
acts in concert with other neuropeptides, such as NPY or POMC in the arcuate 
nucleus (ARC) (Griffond and Risold, 2009), and orexin in LHA (Guan et al., 2002). 
However, there is a general lack of information regarding the interaction with other 
hypothalamic systems. Opioid receptors are widely expressed within the 
hypothalamus (Mansour et al., 1994), and we have previously demonstrated that the 
k-OR system in the ARC is able to modulate the orexigenic effect of ghrelin 
(Romero-Picó et al., 2013). A potential interaction among MCH and the opioid 
system to regulate food intake and food addiction was postulated previously (Lopez et 
al., 2011), but the mechanistic aspects and the specific brain areas where this 
interaction occurs remain unexplored. Since LHA seems to be a link between 
homeostatic and hedonic centers controlling feeding behavior, and k-OR co-localizes 
with MCH receptor in the LHA (Imbernon et al., 2016), we investigated whether 
MCH may act via the opioid system within this hypothalamic area to drive acute food 
consumption. 
 
 Here we use multiple pharmacological and genetic approaches to provide 
evidence that MCH-induced food intake is mediated through the activation of k-OR 
signaling specifically within the LHA. This MCH/k-OR interaction involves reduced 
phospho-S6, and the functional relevance of this mechanism was demonstrated by the 
*Manuscript
Click here to view linked References
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fact that genetic constitutive activation of p70S6K in the LHA blocked MCH-induced 
feeding. These results confirm the relevant role of the hypothalamic kappa opioid 
system as a modulator of MCH orexigenic effect; positioning k-OR as a common 
neuronal signaling pathway integrating central orexigenic signals.  
 
2. Material and methods 
2.1. Animal Procedures and Chemicals 
 Male Sprague-Dawley rats (200-250 g) were housed individually and 
maintained on 12:12-h light-dark cycle at constant temperature (211ºC) and 
humidity (40-50%). They were allowed ad libitum access to water and standard chow 
from Scientific Animal (proteins 16%, carbohydrates 60%, and fat 3%). In all 
procedures implying surgery, rats were anesthetized by an intraperitoneal injection of 
ketamine-xylacine (ketamine 100mg/Kg BW + xylazine 15 mg/Kg BW).  
 Adult (8-10 weeks old) wild type (WT) C57BL6 mice, mutant mice (Oprk1
-/-
) 
that lack functional k-OR subtype 1 (B6.129S2-Oprk1
tm1kff
/J, The Jackson 
Laboratory) (Imbernon et al., 2016; Romero-Picó et al., 2013), were maintained on an 
ad libitum chow diet in Specific Pathogen Free (SPF) conditions and housed with a 
12:12-h light-dark cycle. For surgery, mice were anesthetized by an intraperitoneal 
injection of 138 mg ketamine/Kg BW + 7 mg xylacine/Kg BW. 
 Intracerebroventricular (i.c.v.) central injections were performed between 
9:00-10:00 am. All animal procedures were conducted in accordance with the 
standards approved by the Faculty Animal Committee at the University of Santiago 
de Compostela, and experiments were performed in agreement with the rules of 
Laboratory Animal Care and International Law on Animal Experimentation. Opioid 
receptors antagonists: naloxone hydrochloride (non-selective) and norBNI (nor-
Binaltorphimine dihydrochloride), a selective k-OR antagonist were purchased by 
Tocris (St Lois, MO, USA). Melanin-Concentrating Hormone (MCH, H-1482) was 
provided by Bachem (Bubendorf, Switzerland).  
 
2.2. Pharmacological studies 
 Two different approaches were addressed in this study. First, to identify MCH 
targets we used two groups: 1) control rats (i.c.v. vehicle) and 2) MCH treated rats 
(i.c.v. MCH). Second, to study the effect of opioid receptor antagonists on acute 
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MCH-induced food intake, rats were fed ad libitum and organized in three groups 
(n=10/per group) receiving double i.c.v. injection: 1) vehicle + vehicle; 2) vehicle + 
MCH; 3) opioid receptor antagonist + MCH. I.c.v. cannulae aimed at the lateral 
ventricle were implanted as describe previously (Romero-Picó et al., 2013). After 5 
days of recovery, opioid receptor antagonist was administered i.c.v. 20 min prior 
MCH injection. The doses employed to inhibit total opioid receptors (naloxone) and 
k-OR (norBNI) was 75 nmol and 40 nmol, respectively (Romero-Picó et al., 2013). 
The dose of MCH utilized to stimulate acute food intake at 2h was 8.4 nmol/rat in 
5l. WT and Oprk-/- mice (n=8 per group) received a single injection of vehicle or 
MCH (4.2 nmol/mouse in 2 l) as previously described (Imbernon et al., 2016). We 
measured food intake over 2h and then animals were sacrificed and brains frozen at -
80 ºC. For molecular studies in rats, we sacrificed the animals at 15, 30, 90 or 120 
min and froze the brains at -80ºC until nuclei isolation.   
 
2.3. Genetic approaches  
 We used adeno-associated viruses (AAV) encoding scramble or short hairpin 
kappa opioid receptor subtype 1 mRNA (shOprk1) as previously described (Imbernon 
et al., 2016; Romero-Picó et al., 2013). Stereotaxic injections of AAV into specific 
brain areas was carried out using previously established coordinates (Imbernon et al., 
2016; Romero-Picó et al., 2013): PVH ( 0.5 mm from the midline, 1.9 mm posterior 
to bregma, and 8 mm ventral from the surface of the skull); ARC ( 0.3 mm lateral, - 
2.8 mm antero-posterior, and 10.2 mm dorso-ventral); LHA ( 2 mm lateral, - 2.85 
mm antero-posterior, and 8.1 mm dorso-ventral). For each nucleus studied we set up 
four groups (n=10 rats /per group): 1) scramble-AVV + vehicle i.c.v.; 2) scramble-
AAV + MCH i.c.v.; 3) shOprk-AAV + vehicle i.c.v.; 4) shOprk-AAV + MCH i.c.v. 
15 days after the stereotaxic surgery, an i.c.v. cannula was implanted in the lateral 
ventricle and 5 days later, we administered vehicle (saline) or MCH i.c.v. and 
measured food consumption at 2h. Then, rats were sacrificed and brains were frozen 
at -80ºC. 
  
 We utilized null adenoviruses (Control-Ad) or adenoviruses encoding a 
constitutively active p70S6Kinase form (CAS6K-Ad) (Blouet et al., 2008) to study 
the molecular cascade involved in MCH action. Plasmid pRK7-HA-S6K1-F5A-E389-
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R3A was courteously gift by Dr. Clémence Blouet. Cloning and package in Ad5-
CMV-GFP adenoviruses was performed at Viral Vector Production Unit (Universitat 
Autònoma de Barcelona). Four groups (n=10 rats per group) were subjected to 
stereotaxic surgery: 1) Control-Ad + vehicle i.c.v.; 2) Control-Ad + MCH i.c.v.; 3) 
CAS6K-Ad + vehicle i.c.v.; 4) CAS6K-Ad + MCH i.c.v. Adenoviruses were 
bilaterally injected in the LHA ( 2 mm lateral, - 2.85 mm antero-posterior, and 8.1 
mm dorso-ventral). One week after surgery, an i.c.v. cannula was implanted and 5 
days later we i.c.v. injected vehicle or MCH. At 2h, we measured food intake and rats 
were sacrificed and brains were stored at -80ºC until analysis.  
 
2.4. RNA isolation and TaqMan 
 Total RNA isolation from PVH, ARC, and LHA was performed following 
TRIZOL Reagent manufacture´s protocol. Reverse transcriptase (RT) and real-time 
PCR (TaqMan) was done as previously described (Lopez et al, 2008). Primers used in 
this study are depicted in Table I (Supplementary information). 
 
2.5. Western Blot 
 Total protein extract was obtained from LHA using lysis buffer (50 mM Tris-
HCl pH=7.5, 1 mM EGTA, 1 mM EDTA, 1% Triton-X100, 1 mM Sodium 
Orthovanadate, 50 mM Sodium Fluoride, 5 mM Sodium Pyrophosphate, 0.27 M 
sucrose). We charged 20 g of total protein in 8-10% SDS-PAGE acrylamide gels. 
Proteins were transferred to Immuno-Blot PVDF membranes (BIORAD) with 0.2 or 
0.45 g pore size. The membranes were subsequently blocked with 3-5% BSA in 
TBS 0.1% tween (TBS-T) for 1h. Membranes were incubated overnight with primary 
antibodies in blocking solution at 1:1000 dilution: goat anti-k-OR (Sigma 
SAB2501442), rabbit anti-phospho-ERK (Cell Signaling #4370), rabbit anti-
p70S6Kinase (Cell Signaling #9202), rabbit anti-phospho-S6 ribosomal protein 
(Ser235/236) (Cell Signaling #2211), mouse anti-S6 ribosomal protein (Cell 
Signaling #2317) and mouse anti--Actin (Sigma A5316). Afterwards, membranes 
were washed three times 10 minutes with TBS-T, incubated 1h with secondary 
antibodies (DAKO) at 1:5000 dilutions, and again washed before protein detection 
using ECL chemiluminescent western blot substrate (Thermo Scientific). Images were 
quantified by ImageJ software.  
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2.6. Immunohistochemistry and GFP visualization 
 Brains were fixed in 4% formaldehyde calcium. Paraffin-embedded coronal 
brain sections (5 m) were dried overnight at 55-60 ºC, de-paraffined with xylene and 
then rehydrated. Antigenic recuperation was performed incubating 20 min at 97ºC in 
a 10 mM Tris-EDTA buffer. For immunohistochemistry (IHC), sections were 
incubated overnight at 4ºC with goat anti-k-OR receptor (Sigma SAB2501442) 
diluted 1:3000, rabbit anti-phospho-S6 (Cell Signaling #2211) (1:200), or rabbit anti-
p70S6Kinase (Cell Signaling #9202) (1:100) in EnVision Flex Antibody diluent 
(DAKO). After three washes, sections were incubated with LSAB-DAKO secondary 
for 30 min. Images were captured in a conventional microscopy (Olympus XC50). 
Quantification of phospho-S6 immuno-positive signal was performed through Frida 
software. 
Immunofluorescence was destined to test specific nuclei injection and co-
localization studies. Sections were incubated with rabbit antibody against green 
fluorescent protein (GFP) (Abcam ab290) (1:1000), goat anti-k-OR receptor (Sigma 
SAB2501442), or rabbit anti-MCHR (Abnova PAB16225). To visualize green 
positive signal, we used a goat anti-rabbit Alexa 488 (for GFP) or donkey anti-goat 
Cy2 (for k-OR) as secondary antibodies (1:500). To visualize red positive signal, we 
used donkey anti-rabbit Cy3 (for MCHR) (Jackson ImmunoResearch laboratories, 
UK). Images were captured in a confocal microscopy (Leica TCS-SP2).  
  
2.7. Statistical Analysis and Data Presentation 
 Results are expressed as mean  SEM. GraphPad Prism (version 4.0) was used 
for the data analysis. Comparison between two groups was performed using an 
unpaired t-test. One-way ANOVA followed by Bonferroni´s multiple comparison test 
was used to compare three treatments (vehicle, MCH, and norBI+MCH). Two-way 
ANOVA was used to examine interactions between variables (k-kOR silencing x 
MCH or S6K activation x MCH effect) followed by a Bonferroni´s post-hoc test. 
Sample size and statistical values are defined in each figure legend. P<0.05 was 
considered statistically significant.  
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3. Results 
3.1. Pharmacological or genetic inhibition of the k-OR System blunts MCH-
orexigenic effect  
 Central MCH administration in rats significantly increased food intake after 
2h (vehicle vs MCH, p<0.01) (Figures 1A and 1B). The orexigenic effect of MCH 
was completely blocked by the general opioid receptor antagonist naloxone (75 nmol) 
(MCH vs MCH+naloxone, p<0.001) (Figure 1A). This effect was likely mediated by 
the k-OR receptor since the specific opioid receptor antagonist norBNI (40 nmol) 
significantly blocked the hyperphagic action induced by MCH at 2h to similar extent 
(MCH vs norBNI+MCH, p<0.05) (Figure 1B). 
Dose of antagonists used were chosen based on a dose- and time-response 
experiment. We found that 30 g/rat (equivalent to 75 nmol naloxone and 40 nmol 
norBNI) (i.c.v.) is the minimal amount required to significantly reduce food intake 
over 1-2h in fasted rats (Supplementary Figure S1A and S1B).  
In our experimental model, we did not include a treatment group with naloxone 
or norBNI alone, without co-injection of MCH, since it was previously demonstrated 
by our group that under the same experimental conditions, the non-selective inhibition 
of opioid system with naloxone, or the pharmacological inhibition of k-OR using 
norBNI have not a per se effect on food intake during the acute measurement of food 
consumption (2h) (Romero-Picó et al., 2013).  
Naloxone and norBNI were delivered 20 min prior to MCH administration. It has 
been shown, that at 20 min, i.c.v. norBNI produces transient effects at both mu- and 
delta- receptors (Horan et al., 1992). Since norBNI is a long-lasting antagonist (up to 
3 weeks in vivo) (Bruchas et al., 2007), we hypothesized that if the effects of norBNI 
mediating MCH-induced food intake were specific, the injection of norBNI 24h prior 
to MCH administration would recapitulate its response. We found that identically to 
20 min prior to MCH injection, norBNI injected 24h prior to MCH blunted its 
orexigenic action (Supplementary Figure S2). Moreover, this additional experiment 
reinforces the fact that norBNI per se has not an anorectic effect 2h after i.c.v.  
    
In order to confirm the physiological relevance of the k-OR system on acute 
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MCH-induced feeding, we i.c.v. administered MCH in mice lacking functional k-OR. 
We found that contrary to the orexigenic effect of i.c.v. MCH in wild type mice, 
MCH was not able to stimulate food intake in Oprk-/- mice (Figure 1C). These results 
demonstrate that MCH needs a functional central k-OR system to stimulate food 
consumption.  
 
3.2. The functional interaction between MCH and k-OR occurs in the LHA  
 Recent data have shown that MCHR/k-OR receptors are co-expressed in LHA 
(Imbernon et al., 2016). To investigate if this coincidence was restricted to the LHA 
or it could be found in other hypothalamic sites, we performed double IHC of MCHR 
and k-OR. Our data showed strong co-localization of both receptors in the ARC 
(Figure 1D-F) and the PVH (Figure 1G-I). Besides this morphological evidence, to 
evaluate the specific hypothalamic nucleus responsible of the MCH-k-OR interaction, 
we stereotaxically delivered AAV encoding a shRNA against k-OR (shOprk1) in 
those places (Figure 2A). Infection efficiency was assessed by expression of GFP 
(Figure 2B-D) and decreased k-OR levels in the PVH (Figure 2E and 2F), LHA 
(Figure 2G and 2H), and ARC (Figure 2I). To exclude any shRNA-induced saturation 
of endogenous neuronal microRNAs pathway potentially masking our results, we 
analyzed mRNA expression of mir124 and mir138 in LHA, two markers of toxicity 
(van Gestel et al, 2014). No changes were observed in the expression of mir124 and 
mir138 after the knockdown of Oprk1 in the LHA compared to AAV encoding 
scramble shRNA, indicating that the use of shOprk1-AAV is viable for mRNA 
Oprk1-silencing (Figure 2J). Of note, we have previously demonstrated that this 
shRNA for k-OR does not affect expression of the other opioid receptors, supporting 
the specificity of this knockdown (Romero-Picó et al., 2013). 
 Then, we analyzed the acute effect of MCH i.c.v. on food intake, and 
expectedly we found that cumulative food intake was significantly increased in 
Control-AAV animals. The orexigenic action of MCH i.c.v. was maintained when k-
OR was down-regulated in the ARC or PVH (Figure 2K). However, when k-OR was 
down-regulated in the LHA, we observed a significant interaction between k-OR 
silencing and MCH orexigenic response (Pinteraction=0.0121, F=7.106, DF=1). While 
control rats treated with MCH showed a marked hyperphagia during the 2h period 
post-injection (Pvh vs MCH<0.0001), MCH-induced food intake was significantly 
decreased when we knocked down the k-OR specifically in LHA (PMCH vs 
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shOprk/MCH=0.0087) (Figure 2K). These results suggest that k-OR signaling in the LHA 
is essential for the effect of MCH on feeding.  
 
3.3. MCH increases phosphorylated levels of ERK in the LHA  
Once we had established that k-OR located in the LHA was contributing to 
MCH-induced hyperphagia, we investigated the downstream molecular mechanisms 
involved in the interaction between MCH and k-OR within the LHA. Since the 
inhibition of k-OR affects the orexigenic MCH response, we postulated that the kappa 
opioid system might act downstream MCH signaling.  
First, we corroborated the accuracy of nuclei isolation by assessing the mRNA 
expression of specific markers, namely pro-opiomelanocortin (POMC) in the ARC, 
corticotropin-releasing hormone (CRH) in the PVH, and proOrexin in the LHA 
(Supplementary figure S3).  
k-OR activation is known to activate extracellular signal-regulated kinase 
(ERK), the c-Jun N-terminal kinase (JNK), and p38 MAPK in vitro and in vivo 
(Bruchas and Chavkin, 2010). Since the best characterized opioid-induced Mitogen-
Activated Protein Kinases (MAPK) network to date is ERK1/2, we analyzed the 
activity of ERK under central MCH stimulation. We observed that MCH induced the 
phosphorylation of ERK in the LHA at 15 min (p<0.05) (Figure 3A). This molecular 
effect rapidly disappeared, with the molecular changes not detected at 30 or 120 min. 
Thus, the rapid phosphorylation of ERK in the LHA after 15 min i.c.v. MCH injection 
denotes an activation of k-OR system by MCH.  The increased levels of phospho-
ERK were accompanied by reduced ribosomal S6 activity in LHA (Figure 3B), since 
rats treated with MCH showed a significant reduction of phosphorylated-S6 form in 
the LHA, an effect absent after 90 min (Figure 3C-I). 
 
3.4. Activation of p70S6Kinase in LHA impairs MCH orexigenic effect 
 If the hypothesis that MCH acts in the LHA by attenuating the S6 activity is 
correct, the activation of its upstream direct regulator would be expected to block the 
orexigenic effect of MCH. In order to test this idea, we injected an adenovirus 
encoding a constitutive active form of p70S6K (CAS6K-Ad) in the LHA (Figure 1A). 
We confirmed the efficiency of the viral vector by detecting increased p70S6K 
protein levels in the LHA 12 days after administration of CAS6K-Ad compared to 
control rats (Figure 4B-D). Although the highest expression of p70S6K was detected 
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at day 12, activation of p70S6K was significant from day 4 (Figure 4E). Next, we 
i.c.v. administered vehicle or MCH (8.4 nmol) in rats previously injected with either 
Control-Ad or CAS6K-Ad in LHA, and we found that the activation of p70S6K in the 
LHA attenuated MCH-induced food intake (PMCH and CAS6K interaction=0.009, F=7.646, 
DF=1) (Figure 4F). A post-hoc test indicated that CAS6K-Ad rats stimulated with 
MCH ate significantly less than control-MCH animals (p<0.05). 
At the molecular level, we confirmed the up-regulation of p70S6K form in the 
LHA under CAS6K-Ad activation (p<0.001) (Figure 4G). On the other hand, to 
further validate the overexpression model we checked the direct downstream target of 
p70S6K. The ratio phospho-S6/S6 increased when p70S6K was constitutively 
activated under MCH i.c.v. stimulation (p<0.05) (Figure 4H). 
 
4. Discussion 
 Molecular/synaptic mechanisms of how MCH controls feeding have 
previously been detailed by the DiLeone group (Georgescu et al., 2005; Sears et al., 
2010). They demonstrated that MCH regulates glutamate receptor activity in the 
nucleus accumbens (NAc), where it acts to modulate feeding behavior. However, 
within the hypothalamus the molecular mechanisms responsible of MCH-induced 
orexigenic response are not resolved. Here, in keeping with previous findings (Lopez 
et al., 2011), we observe that central non-selective pharmacological inhibition of the 
opioid system with naloxone impairs acute MCH-induced appetite. Furthermore, our 
results also document that the kappa opioid system located in LHA plays an important 
role in modulating the MCH-mediated orexigenic response in rats. Certainly, the 
degree of blockade observed for virogenetic-induced knockdown of k-OR in the LHA 
was lower than for the i.c.v. pharmacological blockade. This observation was 
somewhat expected since it is well known that a lower number of neurons are affected 
by the virogenetic approach. Moreover, we cannot rule out a potential extra-
hypothalamic MCH action through k-OR system. Indeed, a good candidate is the NAc 
where MCHR1 is strongly expressed. Further studies to address this issue are clearly 
merited.  Whatever the explanation, our data conclusively show that within the LHA 
the mechanism of action of MCH involves the hypothalamic k-OR system and led us 
to hypothesizes that that k-OR system may play an important role modulating the 
acute MCH orexigenic response similarly to what occurs with ghrelin in ARC. 
Noteworthy, we previously demonstrated that the blockade of k-OR signaling in ARC 
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is sufficient to interfere with the orexigenic ghrelin response mediated by NPY in an 
AMPK-independent manner (Romero-Picó et al., 2013).  
  The role of the opioid system on feeding regulation is well established 
(Bodnar, 2015; Gosnell et al., 1986; Nogueiras et al., 2012). Within the mesolimbic 
dopamine reward system, opioids promote appetite for palatable foods through the 
ventral tegmental area (VTA) and the NAc network (Noel and Wise, 1995). Besides 
the hedonic aspects of feeding regulation by the opioid system, opioid receptors are 
widely expressed in the hypothalamus (Mansour et al., 1994) and interact with 
homeostatic signals to control food intake. Indeed, the cross-talk between the opioid 
system and ARC neuropeptides, such as POMC (Pennock and Hentges, 2011), AgRP 
(Hagan et al., 2001), and NPY (Kotz et al., 1993; Schick et al., 1991) has been 
previously described. MCH receptors and k-OR are co-localized in different 
hypothalamic areas including ARC, PVN, and LHA, however we found that MCH-
induced hyperphagia was prevented by genetic inhibition of Oprk1 only in LHA, 
indicating that this hypothalamic area is the most relevant for MCH/k-OR interaction 
in terms of food intake. Nevertheless, it is becoming clear that the functional 
interaction of the k-OR- and MCH-systems is likely to go further than the effect 
described here. The presence of k-OR in MCH neurons indicates that the activity of 
MCH neurons is also regulated by endogenous opioid-neurons. In fact it is known that 
dynorphin neurons are co-localized  with MCHR1  neurons (Chee et al 2013)  and 
that  k-OR is co-localized with MCH neurons (Parks et al., 2014). These anatomical 
and biochemical findings imply strong functional relationships between the two 
systems. Further studies assessing the role of the k-OR as a potential mediator of 
MCH in other brain systems like dopaminergic reward areas such as the NAc and 
VTA are warranted. Similarly, the functional significance of the k-OR in MCH 
neurons and putative regulation by endogenous opioid peptides needs to be 
uncovered. 
The LHA is historically considered as a feeding center that connects the homeostatic 
circuitries to the hedonic ones (Castro et al., 2015). While MCH is mainly produced 
in the LHA, MCH neurons project to numerous hypothalamic and extra-hypothalamic 
areas, where MCHR is expressed at the post-synaptic level. Thus, MCH does seem to 
have a role in the LHA through its interaction with k-OR system, despite the low 
levels of MCH receptors detected in this area (Chee et al., 2013). Although we found 
a clear crosstalk between MCH and k-OR in the LHA, we cannot rule out that this 
11 
 
interaction may also cause molecular changes on extra-hypothalamic nuclei to where 
MCH neurons project, such as VTA or NAc. Further experiments are necessary to 
answer these questions and to elucidate the whole MCH neuronal network.  
 
 Importantly, our data show that the crosstalk MCH/k-OR reaches the 
physiological target of the growth factor-activated p70S6K, namely the 40S subunit 
of the S6 ribosomal protein that play a key role in modulating translational efficiency. 
The phosphorylation of S6 ribosomal protein is a valuable hallmark of neuronal 
activity and its biological role in the brain is one of the major challenges nowadays. 
p70S6K possesses autoinhibitory and catalytic domains. Activation of p70S6K occurs 
through a complex series of phosphorylation events on eight or more serine or 
threonine residues. As reviewed by Dufner and Thomas (Dufner and Thomas, 1999), 
these phosphorylation sites are S404, S411, S418, S424 and T421 on the C-terminal 
autoinhibitory domain and T229, S371 and T389, which are critical for catalytic 
activity. Autoinhibitory sites, on the other hand, are thought to be phosphorylated by 
members of the mitogen-activated protein kinase (MAPK) family, p38 and ERK 
(Mukhopadhyay et al., 1992) and elicit a conformational change to facilitate 
phosphorylations in the catalytic domain. Previous studies linked ERK with the 
regulation of S6K (Lee et al., 2016). Although these studies were undertaken in a 
different context, during dopaminergic neuronal differentiation of human neuronal 
stem cells, the authors observed that the increase in phospho-ERK was accompanied 
by a reduction in phospho-p70S6K. Conversely, inhibition of ERK significantly 
increased the levels of phospho-p70S6K without activation of Akt and mTOR, 
indicating that ERK might directly inhibit p70S6K.  Due to the complexity of p70S6K 
activity, we decided to focus on its direct downstream target in order to identify if k-
OR activation by MCH and increased phosphorylated ERK (phospho-ERK) levels 
would imply changes in the active (phosphorylated) form of S6. Our results show that 
in vivo the increased level of phospho-ERK induced by i.c.v. MCH administration 
was accompanied by a significant reduction of phospho-S6 protein levels at 15 min. 
This observation also suggests that p70S6K is regulated by ERK signaling pathway 
during the acute control of food intake in vivo studies. This rapid response mediated 
by the activation of k-OR might trigger other molecular cascades to regulate food 
consumption since the highest orexigenic physiological response induced by MCH is 
observed at 2h where molecular changes in phospho-ERK and phospho-S6 are absent. 
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Nevertheless, this is the first report of the link between hypothalamic k-OR activation 
and the regulation of p70S6K pathway through MCH in the central nervous system 
(CNS), demonstrating the crosstalk between ERK and S6 during acute food intake 
regulation mediated by MCH. 
 
Finally, it has been previously reported that depression of p70S6K pathways 
in the mediobasal hypothalamus (MBH) during fasting promotes cellular mechanisms 
to stimulate appetite whereas the specific activation of p70S6K reduces food intake 
and protects against the adverse effects of a high fat diet (Blouet et al., 2008). Our 
findings indicate that the activation of p70S6K in LHA decreases the food intake 
promoted by MCH, thus providing additional evidence of the relevance of this kinase 
on the control of appetite.  
 
5. Conclusion  
 In summary, we describe a novel interaction by which the ERK and 
p70S6K/S6 cascades are modulated by MCH through k-OR activation during the 
acute MCH-induced orxigenic response. We found that (a) administration of MCH 
rapidly activates k-OR in the LHA and increases phospho-ERK protein levels; (b) 
elevated phospho-ERK levels reduce S6 activity in this area; and (c) at the functional 
level, constitutively activation of S6 upstream kinase (p70S6K) in LHA significantly 
decrease the acute food intake induced by MCH. Thus, our findings indicate that k-
OR integrates central MCH signaling with the p70S6K/S6 pathway to regulate the 
action of MCH on acute food intake regulation (Figure 5).  
Taking into account that MCH plays a major role in the control of energy 
homeostasis, and that MCH receptor antagonists are in the pipeline of several 
pharmaceutical companies, our data support the relevance of the hypothalamic kappa 
opioid system as a potential drug target. In keeping with this, the recent approval of 
non-selective opioid receptor antagonists for treatment of obese patients adds 
translational value to our findings.  
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Figure Legends  
 
Figure 1. Central blockade of kappa opioid receptor (k-OR) disrupts MCH orexigenic 
response in rats and mice animal models. (A-B) MCH-stimulated food intake upon 2 
hours after intracerebroventricular (i.c.v.) pre-administration of either vehicle or (A) 
75 nmol naloxone or (B) 40 nmol norBNI in rats (n=10 per group). (C) MCH-induced 
food consumption 2 hours after i.c.v. injection of either vehicle or 4.2 nmol MCH in 
wild type (WT) mice (n=12-13 mice/group), and mutant mice for functional k-OR 
(Oprk1-/-) (n=10-11 mice/group). (D-I) Representative images of two-color 
immunofluorescence showing a subpopulation of ARC neurons that exhibits 
immunoreactivity for (D) MCHR (in red), (E) k-OR (in green) and (F) a merged 
image of the two. Corresponding immunofluorescent labeling was also carried out in 
the PVH: singly-labeled neurons appear either (G) red or (H) green, whereas (I) co-
expression (arrowhead) is indicated by yellow. Scale bars: 75 m. Bar graphs on the 
right indicate the degree of co-expression. Values are represented as means  SEM. 
Acute food intake in (A-B) rats was analyze by one-way ANOVA followed 
Bonferroni´s multiple comparisons, while food consumption in (C) mice was 
evaluated by a student t-test. * represents differences compared to vehicle and # 
indicates differences compared to MCH-treated animals.  
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Figure 2. Blockade of k-OR in the LHA using an AAV-particles lead to a reduction 
of food intake elicited by MCH. (A) Illustration of the specific rat hypothalamic 
nuclei (PVH, ARC, and LHA) where shOprk1-AAV were injected to knockdown k-
OR signaling. (B-D) Representative GPF visualization of targeted hypothalamic 
nuclei: (B) PVH, (C) ARC, (D) LHA. Scale bars: 500 m. (E-F) Demonstration of k-
OR silencing by immunohistochemistry after 2 weeks of either (E) Control-AAV or 
(F) shOprk-AAV injection in PVH. Scale bars: 500 m. (G-H)) mRNA Oprk1 or 
protein expression of k-OR after shOprk-AAV injections in LHA measured by (G) 
TaqMan and (H) western blot (n=8 per group). (I) mRNA Oprk1 levels in ARC 
following injection of either Control-AAV or shOprk1-AAV into this nucleus (n=8 
per group).  (J) mir124 and mir138 mRNA expression in LHA to test the viability of 
shOprk-AAV once targeted into the LHA (n=8 per group). (K) Food intake 
stimulated by MCH (8.4 nmol) in rats at 2 hours under specific silencing of k-OR into 
the PVH (n=10 per group), ARC (n=10 per group), or LHA (n=20 per group). Values 
are expressed as means  SEM. Student t-test was performed to (E-I) confirm 
significant reduction of k-OR receptor, or (J) assay mir124 and mir138 expression. 
Two-way ANOVA followed by Bonferroni´s multiple comparison was used to 
evaluate the interaction MCH/k-OR system on food consumption. a=MCH orexigenic 
effect (p<0.001), b=shOprk-AAV knockdown effect, and c=significant MCH/shOprk-
AAV kockdown interaction (p<0.05) in (K) rats stereotaxically treated with either 
Control-AAV or shOprk-AAV in LHA. 
 
Figure 3. Rapid activation of k-OR mediated by MCH lead to a reduction of 
phosphor-S6 in LHA. (A) Western Blot for phosphorylated levels of ERK performed 
in LHA rat samples, and normalized against -actin after 15, 30, and 120min i.c.v. 
MCH (8.4 nmol) administration (n=8 per group). Lines reflect the cropped sites of the 
western blot images. (B-I) Immunohistochemistry detection of (C-I) phospho-S6 
(pS6) expression, and (B) localization in LHA in rats treated with (C, G) vehicle, (D, 
H) MCH (8.4 nmol), and (E, I) norBNI (40 nmol)/MCH (8.4 nmol) at (C-E) 15 min, 
and (G-I) 90 min (C) (n=6-10 per group). Scale bars: (B) 2mm; (C-I) 500 mm. Bar 
graphs on the right indicate the protein levels expressed as percentage normalized to 
vehicle group. Values are represented as means  SEM. For all pairwise comparisons 
a (A) student t-test was used, whereas in cases with three groups, a (C-I) one-way 
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ANOVA followed Bonferroni´s multiple comparisons were used. * indicates 
differences compared to vehicle and # indicates differences compared to MCH-treated 
animals.  
 
Figure 4. Constitutive activation of p70S6K (CAS6K) in LHA decreases the food 
intake in rats centrally treated with MCH. (A) Injection of Ad vectors encoding for a 
green fluorescent protein (GFP) to test a specific site of expression in LHA. Scale bar: 
1mm.  (B-D) Immunohistochemistry protein detection of p70S6K in either (B) 
Control-Ad or (C) CAS6K-Ad rats (n= 4 per group), and (D) negative control. Scale 
bars: 500 mm. (E) Western blot for p70S6K performed in LHA samples and 
normalized against -actin from day 0 (control) to day 12 (n=4 per group). (F) 
Cumulative food intake stimulated by i.c.v. MCH (8.4 nmol) at 2 h under the 
activation of p70S6K using CAS6K-Ad particles (n=10 per group). (G) Protein levels 
of p70S6K measured by western blot and corrected by -actin in either Control-Ad or 
CAS6K-Ad vehicle rats. (H) Ratio of phosphor-S6/S6 analyzed by western blotting 
and normalized against  -actin to validate the constitutively activation of p70S6K 
(n=10 per group).  Values of bar graphs are represented as means  SEM. Two-way 
ANOVA followed by a Bonferroni´s Multiple Comparison was used to (F) evaluate 
the interaction between CAS6K activation and MCH orexigenic effect. a=MCH 
significant effect, and c=significant interaction. Student´s t-test analysis was used to 
evaluate (E) the expression of p70S6K over 12 days in rats treated with CAS6K-Ad 
compared to control rats, and (G, H) the activation of p70S6K/S6 pathway in CAS6K-
Ad rats compared to Control-Ad animals. P<0.05 was considered statistically 
significant (*p<0.05, **p<0.01, ***p<0.001) compared to Control-Ad group. 
 
Figure 5. Scheme summarizing the mechanism of action used by MCH in the 
LHA to regulate the acute food intake. (A) i.c.v. MCH administration rapidly 
activates k-OR by enhancing phospho-ERK, and the activation of k-OR has an 
inhibitory effect on p70S6K/S6 pathway leading to an increase of food intake over 2 
h. The reduction of appetite caused by (B) pharmacological inhibition of k-OR 
(norBNI) or (C) CAS6K-Ad activation in LHA demonstrate a crosstalk between the 
physiological orexigenic response of MCH and these two systems.  
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